News & Events

Learn about what's new with CMC Biologics

CMC Biologics and MacroGenics Enter into Process Validation and Clinical Manufacturing Agreement for Commercialization of Next-Generation Oncology Product Candidate


Seattle, Wash. – June 17, 2014CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into a Master Services Agreement for process validation activities and clinical manufacturing of another of MacroGenics’ oncology product candidates.

Follow Us
Join us on LinkedIn Follow us on Twitter